TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioural Therapy to Optimize Post-Operative Recovery Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men or women aged 18 years and older.~* Presenting to fracture clinic within 2-12 weeks following an acute open fracture of the appendicular skeleton or closed fracture of the lower extremity or pelvis. Patients with multiple fractures may be included.~* Fracture treated operatively with internal fixation.~* Willing to participate in CBT~* Language skills and cognitive ability required to participate in CBT (in the judgement of site research personnel).~* Consistent online access from a smartphone/internet-enabled device with a minimum operating system able to use the CBT provider application or videoconferencing software applications.~* Provision of informed consent.~Exclusion Criteria:~* Fragility fracture.~* Stress fracture.~* Fracture of the hand.~* Fracture of the foot.~* Concomitant injury which, in the opinion of the attending surgeon, is likely to impair function for as long as or longer than the patient's extremity fracture.~* Active psychosis.~* Active suicidality.~* Active substance use disorder that, in the judgement of the treating surgeon, would interfere in the patient's ability to partake in the CBT and/or the trial.~* Already participating in, or planning to, start other psychological treatments (including CBT) within the duration of the study (12 months).~* Anticipated problems, in the judgement of study personnel, with the patient participating in CBT intervention and/or returning for follow-up.~* Incarceration.~* Currently enrolled in a study that does not permit co-enrolment in other trials.~* Previously enrolled in the COPE trial.~* Other reason to exclude the patient, as approved by the Methods Centre.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention - CBT (Type: EXPERIMENTAL): Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
- No intervention- - control (Type: NO_INTERVENTION): Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin for Post Exposure Prophylaxis of Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Asymptomatic individuals exposed to a confirmed positive COVID-19 case within 5 days from the study recruitment day (include household, workplace and social close contact)~2. Aged ≥18 years; male or female~3. No fever with temperature less than 37.5ºC~4. RTK Ag for COVID-19 is negative on the recruitment day.~5. For subject who had received COVID-19 vaccination:~   * Any primary series vaccine (eg: Pfizer, Sinovac, AstraZeneca etc) : past 90 days after the second dose~  * Any booster vaccine: past 90 days after the booster dose~6. In women of childbearing potential (18-55 years old), negative pregnancy test and agree to use any contraceptive method up to 7 days after the second dose of IP administration~7. Have access to video and phone call~8. Willing to take 2 doses of study medication (2 days apart between Dose 1 and Dose 2)~9. Willing to comply with all study procedures~10. Able to provide written informed consent~Exclusion Criteria:~1. Unable to take drugs by mouth~2. History of positive confirmed COVID-19 infection within past 3 months~3. Involved in any COVID-19 vaccine clinical trial~4. Patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug~5. Known case of liver disease (any severity)~6. Alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women)~7. Mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others).~8. Pregnant or nursing/breastfeeding women or women planning for pregnancy.~9. Female patients who cannot consent to contraceptive use (any method) from the start of IP administration to 7 days after the second dose of IP administration~10. Male patients whose partner cannot agree to use the contraception method as in 9)~11. Patients with a history of gout or on treatment for gout or hyperuricemia~12. Patients receiving immunosuppressant~13. Patients who have previously received Ivermectin.~14. Patients who are not able to provide written consent.~15. Other patients judged ineligible by the principal investigator or sub-investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group: (Type: ACTIVE_COMPARATOR): Ivermectin 0.4 mg/kg/day (maximum 24 mg)
- Control group (Type: PLACEBO_COMPARATOR): Placebo-inactive substance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who have coronary stenoses between 40-70% severity and who have severe aortic stenosis undergoing TAVR work-up.~Exclusion Criteria:~* Patients with documented intraprocedural hemodynamic instability, shock, or major adverse event (myocardial infarction, aortic rupture/dissection, stroke, left ventricular perforation, cardiac arrest).~* Contraindication to adenosine, presence of cardiogenic shock, presence of acute coronary syndrome.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- FFR/iFR arm (Type: EXPERIMENTAL): Volcano iFR/FFR Verrata Plus coronary pressure/flow wire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* in follow-up after endovascular implantation of abdominal aortic prothesis~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Cooking and Eating Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PCOS.~* Aged 13 to 21 years (and living at home with a parent, only for those \<18 years old).~* Body mass index (BMI) at or above the 85th percentile.~* Access to a working telephone.~* At least one parent willing and able to participate in the intervention, only for those \<18 years old.~* Residing in predominately one household (no more than one weekend every two weeks in a secondary household).~* Medical clearance from the physician who is treating PCOS.~Exclusion Criteria:~* Physician diagnosis of a major medical illness or eating disorder.~* Fasting blood glucose at or above 126 mg/dL, indicating diabetes mellitus.~* Chronic use of any medication that may affect study outcomes.~* Current smoking.~* Physical, mental, or cognitive handicaps that prevent participation.~* Sister participating in the study.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Low-glycemic Load Diet (Type: EXPERIMENTAL): None
- Low-fat Diet (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Swiss Prospective Autologous Bone Flap Resorption Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients after hemicraniectomy or bifrontal craniectomy~* age 18-99 y/o~* ability to understand and sign informed consent (alternatively, legal representative may sign)~Exclusion Criteria:~* bone flap not fit for reimplantation~* no cryoconservation performed but other technique~* pregnancy~* patient's death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Reimplantation of cryoconserved bone flap (Type: None): All patients who receive reimplantation of a cryoconserved autologous bone flap

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Pregnancies After Cryopreservation of Donor Oocytes With an Open or Closed Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* this is a pragmatic randomized clinical trial. Hence, all consenting oocyte recipients will be eligible for the study~Exclusion Criteria:~* women who do not consent or that cannot comprehend the investigational nature of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 47 Years
- Healthy Volunteers: t

Study Arms:
- closed device (Type: PLACEBO_COMPARATOR): Standard cryopreservation system.
- open device (Type: ACTIVE_COMPARATOR): New cryopreservation system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients above 18 years of age scheduled for cardiac surgery~* Excessive postoperative bleeding, more than 250 ml for one hour, or more than 150ml for two hours during the first four hours~Exclusion Criteria:~* Patients younger than 18 years of age~* Patients with a medical condition known to influence the hemostatic system~* Patients treated with clopidogrel or systemic steroids during the last week before surgery~* Patients with INR above 1.5~* Patients who are not able to give written informed concent~* Unstable patients who need other transfusion limits than in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: ACTIVE_COMPARATOR): Desmopressin 0.3 microgram/kg
- Placebo (Type: PLACEBO_COMPARATOR): NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years,~* has tinnitus~Exclusion Criteria:~* Pacemaker,~* pregnancy,~* metal implants in head or neck,~* thrombosis, migraines/headaches,~* metal bonded retainer, surgeries within the last 6 months which patient is still recovering from,~* any medical reason your physician would advise against the use of this device,~* under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tinnitus (Type: EXPERIMENTAL): Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device.
- No tinnitus (Type: NO_INTERVENTION): Individuals without tinnitus will also be masked with the device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients at 15-65 years of age undergoing renal transplantation~* Patients who have been informed of the potential risks and side effects of the study~* Patients who have given written informed consent to participate in the study~* Females who are not pregnant or nursing women (pregnancy test required)~Exclusion Criteria:~* Donor age greater than 65 years~* Patients receiving a perfectly matched kidney (6 matches HLA A, B, DR)~* Patients who are recipients of multiple solid organ transplants~* Patients undergoing second or subsequent transplantation~* Patients with pre-transplant PRA \> 30%~* Patients with ABO incompatibility or positive lymphocytotoxicity~* Patients with severe, active infection~* Patients who have an abnormal liver profile such as ALT, AST, alkaline phosphatase or total bilirubin \>3 times the upper normal limit~* Patient who are HIV-positive or hepatitis C (PCR+ only) B surface antigen positive~* Patients who have been treated with an investigational drug or therapy within one month prior to entry or who will be so treated within 6 months of transplantation~* Patients with a history of malignancy within the last five years except excised squamous or basal cell carcinoma~* Patients with a history of alcohol or drug abuse or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to comply fully with the study requirements.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- rituximab and everolimus (Type: ACTIVE_COMPARATOR): Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
- thymoglobulin and tacrolimus (Type: ACTIVE_COMPARATOR): The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \> 18 years are eligible.~2. Patient must provide informed consent to participate in the study protocol.~3. All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).~4. Planned plasma cell-directed chemotherapy.~5. A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.~6. Patients must be able to undergo PET-CT imaging~7. Patients must be able to complete 6-minute walk test~Exclusion Criteria:~1. Severe claustrophobia~2. Pregnancy~3. Allergy to F-18 florbetapir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with AL cardiac amyloid (Type: EXPERIMENTAL): Patients enrolled will be patients \> 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>= 18 years old~* Patients with colon or rectal carcinoma histologically proven~* Patients with metastases (synchronous or metachronous)~* Patients with associated extra-hepatic disease (asymptomatic primary tumor or extra-hepatic metastases)~* Performance status (World Health Organization \[WHO\]) = 0, 1, or 2~* Life expectancy \>= 3 months~* Patients with normal haematological, kidney, and liver parameters (PNN \> 1.5 x 10\^9/L, platelets \> 100 10\^9/L, total bilirubin \<= 1.25 x upper limit of normal (ULN), ASAT/ALAT \<= 5 x ULN, creatinaemia \<= 135 µmol/L (1.5 mg/dL)~* No cardiac or coronary insufficiency untreated~* At least 4 weeks between surgery and study beginning~* Patients can have a biopsy of the hepatic lesion identified by ultrasound.~* Informed consent signed.~Exclusion Criteria:~* Patients with symptomatic tumors (colon or rectal)~* Patients with others tumors not cured~* Patients who cannot be treated by 5-fluorouracil (5-FU) and/or irinotecan because of special medical conditions or other serious disease.~* Patients who participated in another clinical trial since less than 30 days~* Pregnancy or breast-feeding women~* Patients who cannot be treated because of active infection or other serious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bevacizumab
- 2 (Type: EXPERIMENTAL): Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cancer~2. Age ≤ 18 years~3. First tunneled central venous catheter (implanted port or external) inserted in the upper venous system (subclavian, brachiocephalic, or jugular vein) within the previous 2 weeks~4. Catheter expected to be in place for duration of chemotherapy (≥ 3 months)~5. History of no more than one catheter complication (occlusion or infection)~Exclusion Criteria:~1. Prior history of DVT~2. Currently receiving an anticoagulant or anti-platelet agents on a daily basis~3. Diagnosis of high grade malignant brain tumor or metastasis to the brain~4. Clinical signs/symptoms of DVT~5. Clinical signs/symptoms of Pulmonary embolism~6. Renal failure~7. Recent major hemorrhage

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A-randomized to treatment (Type: EXPERIMENTAL): Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
- B-randomized to close (Type: NO_INTERVENTION): Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy